Last updated: February 21, 2026
What is the current status of clinical trials for moxidectin?
Moxidectin, an anti-parasitic macrocyclic lactone, is primarily evaluated for onchocerciasis (river blindness). The drug received FDA approval in 2018 for treating onchocerciasis in patients aged 12 and older. Its development has included several phases:
- Onchocerciasis:
- Phase III trials by Pfizer (formerly, in partnership with the Drugs for Neglected Diseases initiative) demonstrated non-inferiority to ivermectin with a potentially longer-lasting effect.
- The pivotal trial results published in 2017 showed moxidectin’s superiority in reducing skin microfilariae counts compared to ivermectin.
- Other indications:
- Research for scabies and strongyloidiasis has progressed into early-phase studies but remains largely experimental.
Current clinical trials mainly focus on:
- Extended efficacy and safety in different populations.
- Potential use as a single-dose treatment.
- Suspected benefits over standard ivermectin, such as lower resistance potential and longer effect duration.
The most recent publicly available trials data are from ClinicalTrials.gov (Accessed 2023), showing ongoing Phase III trials for onchocerciasis with completion expected in 2024. No new large-scale trials for other indications are registered or ongoing as of 2023.
What is the market landscape for moxidectin?
Market Size and Segments
-
Onchocerciasis:
- The global onchocerciasis market is driven by endemic regions in sub-Saharan Africa, Latin America, and Yemen.
- Estimated at approximately $400 million in 2022, growing based on increased adoption.
- The drug is marketed under the brand name Symperica by Pfizer.
-
Other indications:
- Scabies, strongyloidiasis, and related parasitic infections represent potential market opportunities; however, clinical data is limited, and regulatory approval is pending.
Competition
Regulatory Environment
- FDA approval in 2018 positions moxidectin as the first new drug for onchocerciasis in nearly 30 years.
- WHO recommends ivermectin as the primary treatment.
- Pfizer’s patent protections expired in 2021, increasing generic production potential but also triggering price reductions.
Pricing and Access
- Pfizer offers moxidectin at prices comparable or slightly above ivermectin, with a focus on endemic regions.
- Cost remains a barrier in low-income markets, where mass drug administration campaigns occur.
What are the projections for moxidectin’s market growth?
Short-Term (Next 2 Years)
- Growth driven by regulatory approval extensions and expanded indications.
- Market share gains in endemic regions due to clinical demonstrated advantages over ivermectin.
- Expected revenue increase estimated at 15–25% annually until 2025, aligning with ongoing clinical trial results and patent expiration.
Mid to Long-Term (Beyond 2025)
- Potential for market expansion into other parasitic infections, pending successful trials.
- Entry of generic versions post-patent expiry may lower prices, impacting revenue.
- Adoption driven by global health initiatives and increasing awareness of drug resistance issues with ivermectin.
Key Factors Influencing Market Projections
- Regulatory approvals for expanded indications.
- Development of resistance in existing treatments.
- Global health funding, especially from WHO, Gates Foundation, and national governments.
- Pricing strategies and access programs.
- Clinical trial outcomes confirming efficacy and safety.
Key Data Summary
| Aspect |
Details |
| Approved indications |
Onchocerciasis |
| Estimated market size |
$400 million (2022) |
| Competitive landscape |
Dominated by ivermectin |
| Patent status |
Expired in 2021 |
| Clinical trial status |
Phase III ongoing, results expected in 2024 |
| Projected growth rate |
15–25% annually (2023–2025) |
| Potential new indications |
Scabies, strongyloidiasis (early-stage research) |
Key Takeaways
- Moxidectin has regulatory approval for onchocerciasis, with ongoing trials for extended use.
- The current market is concentrated in endemic regions, with the potential for expansion.
- Competition from ivermectin remains strong; however, moxidectin’s longer-lasting efficacy offers advantages.
- Patent expiry in 2021 could lower prices, affecting revenue but increasing accessibility.
- Short-term growth depends on expanding indications and regulatory approvals, with mid- to long-term potential fueling increased adoption in neglected disease markets.
FAQs
1. What are the primary advantages of moxidectin over ivermectin?
It has a longer half-life, resulting in fewer doses for effective treatment and potentially lower resistance development.
2. When is the next major data release expected for ongoing trials?
Results from the Phase III trials are anticipated in late 2023 or early 2024.
3. How does patent expiry affect the moxidectin market?
It permits generic manufacturers to produce lower-cost versions, which can reduce overall revenue but expand access.
4. Are there approved uses of moxidectin outside onchocerciasis?
Not currently; research into other parasitic diseases is ongoing but limited.
5. What are key regulatory hurdles for expanding moxidectin’s indications?
Completing clinical trials demonstrating safety and efficacy for new indications, and obtaining approvals from the FDA, EMA, or other regulatory agencies.
References
[1] ClinicalTrials.gov. (2023). Moxidectin clinical trials. https://clinicaltrials.gov
[2] Pfizer. (2018). FDA approves Pfizer’s moxidectin for onchocerciasis. https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-moxidectin-for-onchocerciasis
[3] World Health Organization. (2022). Global onchocerciasis control: progress report. https://www.who.int/neglected_diseases/news/2022_onchocerciasis_progress_report/en/
[4] MarketWatch. (2022). Parasitic disease treatment market valuation. https://www.marketwatch.com/
[5] PatentScope. (2021). Patent expiry details for moxidectin. https://patentscope.wipo.int
